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Background: Capecitabine, an orally administered ﬂ  uoropyrimidines, is widely used in 
the treatment of multiple malignancies. It has been extensively evaluated in patients with 
gastroesophageal carcinoma. Since recent reviews have discussed phase I/II trials (Cancer 
107:221–231, 2006; Drugs 67:601–610, 2007), we focus on the impact of the results of the 
most current phase III trials using capectiabine in the treatment of advanced gastroesophageal 
cancers, primarily in the ﬁ  rst-line setting. 
Methods: To ﬁ  nd published phase III trials, Medline was searched for English-language 
clinical trials published from 1996 through June 2007 along with relevant abstracts presented 
at the American Society of Clinical Oncology, and meetings of the European Cancer Confer-
ence and European Society of Medical Oncology. Only representative trials were chosen for 
this manuscript.
Results: The most frequently investigated combinations are capecitabine with taxanes, 
platinols, and camptothecins. Recent results of a large phase III trial (REAL-2) in untreated 
patients with gastroesophageal cancer suggest that capecitabine is a non-inferior substitute for 
intravenous 5-ﬂ  uorouracil. These results of REAL-2 trial are substantiated by a smaller phase 
III trial. Previous analysis of multiple trials had suggested that capecitabine, when combined 
in doses lower than 1250 mg/m2 twice daily, consistently resulted in lower frequency of Grade 
3 or 4 toxic effects.
Conclusions: Capecitabine provides much needed convenience to patients with gastroesopha-
geal cancer. The recent data derived from two phase III trials conﬁ  rm that capecitabine is a 
suitable substitute for intravenous 5-ﬂ  uorouracil in patients whose swallowing is not greatly 
affected. Capecitabine remains a subject of further investigations in this group of patients with 
interest.
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Introduction
Gastroesophageal cancers represent a major health care burden throughout the world. 
The incidence in the USA is relatively low and has resulted in considerable lack of 
much needed research in this area. Adenocarcinoma involving the gastroesophageal 
junction and proximal stomach is on a rapid rise in the West (Phol and Welch 2005). 
The combined incidence of gastroesophageal cancer exceeds 1.4 million cases per 
year (Cancer Facts and Figures 2006) and among these gastric cancers make up the 
fourth most common cancer worldwide, with 934,000 new cases per year, and the 
second most common cause of cancer-related death, with 700,000 deaths annually 
(Cancer Facts and Figures 2006). 5-ﬂ  uorouracil (5-FU) is one of the most commonly 
used drugs in patients with advanced gastroesophageal cancer. It has been used more 
consistently than any other class of agents. However, depending on the schedule and 
dose of 5-ﬂ  uourouracil, patient may experience considerable toxicities. Currently, Therapeutics and Clinical Risk Management 2008:4(1) 138
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one stated goal for the future development of cytotoxic 
combinations in patients with advanced gastric cancer is to 
focus on therapy that is more convenient, has a favorable 
safety proﬁ  le but without compromise of the efﬁ  cacy. 
Oral ﬂ  uoropyrimidines have the potential to fulﬁ  ll the 
two of the stated goals for improving the overall proﬁ  le of 
cytotoxic combination chemotherapy. S-1, an agent not avail-
able widely, is approved for the treatment of advanced gastric 
cancer in Japan and Korea, and has been investigated on a 
limited basis in the West (Schuller et al 2000; Chollet et al 
2003; Ajani et al 2005, 2006; Lenz et al 2007). Capecitabine, 
on the other hand, has been a subject of investigation in 
patients with gastroesophageal cancers for some time as 
reviewed recently (Ajani 2006; Dhillon and Scott 2007). 
Here we focus mainly on the current research involving 
phase III studies performed with capecitabine in combination 
with other agents in the treatment of patients with advanced 
gastroesophageal cancers. 
Capecitabine is a novel, orally administered ﬂ  uoropyrimi-
dine carbamate that is readily absorbed by the gastrointestinal 
tract and is metabolized by the liver, where it is converted 
initially to 5′deoxy-5-ﬂ  uorocytidine (5′-DFCR) and subse-
quently to 5′deoxy-5-ﬂ  uorouridine (5′-DFUR). Designed 
to mimic continuous intravenous infusion of 5-ﬂ  uorouracil 
(5-FU), oral capecitabine predominantly concentrates in 
tumor tissue (Roche Laboratories Inc 2005). Capecitabine is 
currently approved as a single agent for adjuvant treatment of 
Stage III colon cancer and for ﬁ  rst-line metastatic colorectal 
cancer (when ﬂ  uoropyrimidine therapy alone is preferred), 
and for metastatic breast cancer as a single agent (for patients 
resistant to paclitaxel and anthracyclines) and in combination 
with docetaxel (after failure of anthracycline-based therapy) 
(Hong et al 2004). 
Absorption and compliance
Capecitabine is fully absorbed from the gastrointestinal 
tract (particularly from the small intestines) unaltered and 
converted to 5′-DFCR and 5′-DFUR to 5-ﬂ  uorouracil (Kochi 
et al 2007) The absorption of oral ﬂ  uoropyrimidines is unaf-
fected by gastrectomy (Camidge et al 2005) Clearly, patients 
who have signiﬁ  cant nausea and/or vomiting are suitable for 
capecitabine therapy. In addition, patients who have dysphagia 
to solids should not be recommended oral therapy, includ-
ing capecitabine. Compliance to oral therapy is certainly an 
important issue. Compliance is highly dependent on the fre-
quency and duration of therapy. Capecitabine is administered 
twice daily for 7–14 consecutive days; therefore, the compli-
ance has not been a signiﬁ  cant issue in these patients. 
Methodology
Medline was searched for English-language clinical trials 
published from 1996 through June 2007 containing the terms 
“capecitabine” or “Xeloda” and “gastric,” “stomach,” “gas-
troesophageal” in the title or abstract. Potentially relevant 
abstracts presented at annual meetings or gastrointestinal 
symposia of the American Society of Clinical Oncology 
(ASCO), and from meetings of the European Cancer Confer-
ence (ECCO) and the European Society of Medical Oncology 
(ESMO), dating back to year 2000 were examined. Only the 
most recent data from reported trials were included.
The focus of this review is predominantly on efﬁ  cacy 
in patients with advanced gastroesophageal cancer and to 
some extent on dose-related toxic effects. The review also 
focuses on mainly on combination of capecitabine with 
other agents and greater description of two newly reported 
phase III trials.
Results
Several phase II trials (Louvet et al 2002; Koizumi et al 2003; 
Kondo et al 2003; Sakamoto et al 2006) have evaluated the efﬁ  -
cacy and safety of capecitabine as a single agent for treatment of 
gastric cancer. Capecitabine has been combined with taxanes, 
platinols, and camptothecins in many phase I and phase II set-
tings, as reviewed previously (Ajani 2006; Dhillon and Scott 
2007). With regards to complications related to capecitabine, 
it was noted from our previous review that patients with who 
received more than 2500 mg/m2 per day of capecitabine in com-
bination with other agents, experienced a high rate of related 
grade 3 or 4 toxicity. Therefore, it was suggested the daily dose 
of capecitabine be reduced to less than 2500 mg/m2/day when 
combined with other cytotoxic agents.
Results of recent phase III studies
Oxaliplatin when combined with 5-ﬂ  uorouracil is active 
against gastric or gastroesophageal carcinoma (Louvet et al 
2002). It has been substituted for cisplatin in a couple of 
recent phase III trials (Cunningham et al 2006; Kang et al 
2006). In the REAL 2 trial, more than 1000 patients were 
randomized in a 2 × 2 design to epirubicin, cisplatin, and 
5-ﬂ  uororuacil (ECF serving as the reference regimen) or to 
3 other regimens that systematically substituted oxaliplatin 
for cisplatin (as in epirubicin, oxaliplatin, and 5-ﬂ  uorouracil 
[EOF] or epirubicin, oxaliplatin, and capecitabine [EOX]) or 
capecitabine for 5-ﬂ  uorouracil (as in EOX or epirubicin, cis-
platin, and capecitabine [EOX]). The primary endpoint of this 
trial was focused on overall survival (OS) (acceptable hazard 
ratio [HR] up to 1.23) to demonstrate the non-inferiority Therapeutics and Clinical Risk Management 2008:4(1) 139
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of capecitabine when substituting it for 5-ﬂ  uorouracil and 
the non-inferiority when substituting oxaliplatin for cisplatin. 
The secondary endpoints were to compare all 4 regimens, 
review safety, and TTP. This trial has mature results. The 
median follow-up time is more than 17 months and more 
than 850 events have already occurred. Overall, the 60-day 
all cause mortality was in the range of 8% for all 4 regimens. 
Similarly, the mortality from 30 days from last chemotherapy 
administration was similar. One-year survival was also very 
similar and so was the median survival per protocol. The HR 
was 0.86 for the primary comparison between capecitabine 
and 5-ﬂ  uorouracil and the HR was 0.92 for the primary 
comparison between oxaliplatin and cisplatin. Non-inferiority 
was maintained for capecitabine (HR = 0.89) and oxaliplatin 
(HR = 0.95) after multivariable analysis was performed with 
performance status, extent of disease, and age included in the 
model. In addition, there was more hand-and-foot syndrome 
in the capecitabine arms and there was more neuropathy in 
the oxaliplatin arms. Finally, all 4 regimens were generally 
well tolerated with, at the most, a 10% rate of complicated 
neutropenia. In addition, the baseline QoL was similar at 
baseline for all 4 arms. After starting protocol chemotherapy, 
QoL at 12 and 24 weeks was also similar in all 4 arms. 
REAL 2 is an important trial that demonstrated that 
capecitabine is non-inferior to 5-ﬂ  uorouracil and oxaliplatin 
is non-inferior to cisplatin. Capecitabine had a different 
toxicity proﬁ  le compared to 5-FU however it was not neces-
sarily better tolerated than 5-FU. In addition, capecitabine 
is probably more convenient for patients but the QoL scores 
are not different between treatments arms.
Kang et al (2006) have conﬁ  rmed the ﬁ  ndings of the REAL 
2 trial in a multi-national phase III trial. In this recently presented 
trial, 316 patients with untreated advanced gastric carcinoma 
received infusional 5-ﬂ  uorouracil 800 mg/m2 on days 1–5 
and cisplatin 80 mg/m2 (FP) administered every 3 weeks or 
capecitabine 1000 mg/m2 twice daily for 14 days and cisplatin 
80 mg/m2 (XP) administered every 3 weeks. The primary end-
point was to demonstrate non-inferiority when capecitabine 
is substituted for 5-ﬂ  uorouracil in OS with acceptable HR of 
 1.4. The trial was conducted in 46 centers and 3 countries. 
The median follow-up time for this trial was 22 months. The 
HR for the primary endpoint was 0.81 (the median survival for 
XP = 10.5 months and that for FP = 9.3; p = 0.27). The toxicity 
proﬁ  le was similar for both regimens. Summary of two recent 
phase III trials using capecitabine is provided in Table 1.
There was no QoL assessment in the Kang et al trial. In 
addition, this trial used lower doses of cisplatin and 5-FU in 
the reference arm as compared to other recent phase III trials 
with FP (Dank et al 2005; Van Cutsem et al 2006). A more 
standard dosing regimen of cisplatin and 5-FU may have 
inﬂ  uenced the ﬁ  nals results. In conclusion, this trial shows 
that capecitabine is non-inferior to 5-ﬂ  uorouracil. 
Conclusions and future directions
Capecitabine is an important agent in the treatment of 
advanced gastroesophageal cancer. It is one of the most 
investigated oral ﬂ  uoropyrimidines. The results of the most 
recent phase III trials demonstrate that capecitabine is non-
inferior to intravenously administered 5-ﬂ  uororuacil. The 
toxicity of capecitabine (particularly hand-foot syndrome 
and diarrhea) is dose dependent. Capecitabine is currently 
being studied in combination with intravenous cytotoxic and 
biologic agents, with radiation therapy and in the adjuvant 
setting. Further studies of capecitabine in combination with 
oral cytotoxic and oral biologic agents are warranted.
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Table 1 Summary of randomized phase III trials investigating capecitabine in advanced gastroesophageal cancer 
  Treatment  Response rate  Median overall  Hazard ratio
   (overall)  survival  (months)  (95%  CI)
Cunningham et al 2006  ECF  41%  9.9   1
 EOF  42%  9.3  0.95  (0.79–1.15)
 ECX  46%  9.9  0.92  (0.76–1.11)
 EOX  48%  11.2  0.80  (0.65–0.97)*
Kang et al 2006  FC  29%  9.3  1
 XC  41%** 10.5  0.81  (0.63–1.04)
*p value = 0.025 compared to ECF.
**p value = 0.03.
Abbreviations: C, cisplatin; CI, conﬁ  dence interval; E, epirubicin; F, 5-ﬂ  uorouracil; X, capecitabine.Therapeutics and Clinical Risk Management 2008:4(1) 140
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